Zhengye Biotechnology Holding Limited specializes in the creation, manufacturing, and commercialization of animal health immunizations. The company primarily supplies the Chinese agricultural sector with vaccines tailored for a broad spectrum of farm animals, including swine, bovines, goats, ovines, and poultry. Additi…
An institutional-grade, numbers-driven thesis on ZYBT — generated on demand from live fundamentals, scores and forecast.
Member feature · 7-day free trial · no charge today · cancel anytime
As of August 18, 2026, TradersQuant's model rates Zhengye Biotechnology Holding Limited (ZYBT) 54/100 with a 12-month base-case forecast of $0.76 — -50.0% versus the current price of $1.52. Zhengye Biotechnology Holding Limited trades at $1.52 in the Healthcare sector, with a market capitalisation of $72.0M. The score blends valuation, growth, earnings quality and momentum into a single grade.
The 12-month TradersQuant model price target for ZYBT is $0.76, implying -50.0% versus the current price. The model's 12-month scenario range runs from $0.66 (bear) to $0.93 (bull), with a base case of $0.76.
On the fundamentals, Zhengye Biotechnology Holding Limited shows a P/E of -6.9, trailing revenue of $16.6M, revenue growth of -37.6% YoY. This page also tracks ZYBT's short interest, institutional (smart-money) positioning and the options market — the same cross-signal view institutions watch.
ZYBT currently carries a TradersQuant composite score of 54/100, which we read as a neutral-to-watch signal. Our 12-month price target of $0.76 implies -50.0% from $1.52. This is research, not financial advice — always combine it with your own judgement.
The TradersQuant 12-month model price target for ZYBT is $0.76, about -50.0% versus the latest price of $1.52.
TradersQuant's 12-month model forecast for ZYBT is a base case of $0.76, ranging from $0.66 (bear) to $0.93 (bull), an expected return of -50.0%. Forecasts are model estimates, not guarantees.
The TradersQuant price prediction for ZYBT over the next 12 months is $0.76 in the base case (bear $0.66, bull $0.93), versus today's price of $1.52. Unlike black-box prediction sites, every TradersQuant call is logged at the price and date it was made and graded publicly against the S&P 500.
We deliberately don't publish 2030 price predictions for ZYBT — no model can honestly forecast a single stock five-plus years out, and sites that do are guessing. TradersQuant focuses on a rigorous 12-month bull/base/bear range, refreshed continuously and graded on our public track record.
TradersQuant estimates ZYBT's fair value at $1.93, implying +27.2% of expected upside versus the current price.
Zhengye Biotechnology Holding Limited does not currently pay a dividend.
Data and model outputs are for research only and are not financial advice. Figures update continuously.
